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Vertebrates produce at least seven distinct-tubulin isotypes
that coassemble into all cellular microtubules. The functional
differences among these tubulin isoforms are largely unknown,
but recent studies indicate that tubulin composition can affect
microtubule properties and cellular microtubule-dependent
behavior. One of the isotypes whose incorporation causes the
largest change in microtubule assembly is 5-tubulin. Overex-
pression of this isotype can almost completely destroy the
microtubule network, yet it appears to be required in smaller
amounts for normal mitotic progression. Moderate levels of
overexpression can also confer paclitaxel resistance. Experi-
ments using chimeric constructs and site-directed mutagenesis
now indicate that the hypervariable C-terminal region of 5
plays no role in these phenotypes. Instead, we demonstrate that
two residues found in 5 (Ser-239 and Ser-365) are each suffi-
cient to inhibit microtubule assembly and confer paclitaxel
resistance when introduced into 1-tubulin; yet the single
mutation of residue Ser-239 in5 eliminates its ability to confer
these phenotypes. Despite the high degree of conservation
among -tubulin isotypes, mutations affecting residue 365
demonstrate that amino acid substitutions can be context sen-
sitive; i.e. an amino acid change in one isotype will not necessar-
ily produce the same phenotype when introduced into a differ-
ent isotype. Modeling studies indicate that residue Cys-239 of
1-tubulin is close to a highly conserved Cys-354 residue sug-
gesting the possibility that disulfide formation could play a sig-
nificant role in the stability ofmicrotubules formedwith1- but
not with 5-tubulin.
Microtubules are needed to organize theGolgi apparatus and
endoplasmic reticulum, maintain cell shape, construct ciliary
and flagellar axonemes, and ensure the accurate segregation of
genetic material prior to cell division. These cytoskeletal
structures assemble from - and -tubulin heterodimers to
form long cylindrical filaments that exist in a state of
dynamic equilibrium characterized by stochastic episodes of
slow growth and rapid shrinkage (1). Impairment of normal
dynamic behavior has serious consequences for cell prolifer-
ation and thus makes microtubules an attractive target for
drug development (2).
Vertebrates express multiple -tubulin genes that produce
highly homologous proteins differing most notably in their
C-terminal 15–20 amino acids (3, 4). These variable C-terminal
sequences are conserved across vertebrate species and have
been used to classify -tubulin genes into distinct isotypes (5).
In mammals, for example, there are seven known isotypes des-
ignated by the numbers I, II, III, IVa, IVb, V, and VI. The func-
tional significance of theC-terminal sequences is uncertain, but
some studies suggest that they may be involved in binding or
modulating the action of microtubule-interacting proteins
(6–14). Additional amino acid differences are scattered
throughout the primary sequence, but the functional role of
these differences, if any, has not been elucidated. Although
some -tubulin isotypes are expressed in a tissue-specific man-
ner (3), evidence indicates that microtubules incorporate all
available isotypes, including transfected isotypes that are not
normally produced in those cells (5, 15–17). Genetic experi-
ments designed to test potential functional differences among
the various-tubulin isotypes have only demonstrated isotype-
specific effects on the assembly of specializedmicrotubule-con-
taining structures such as flagellar axonemes in Drosophila or
15-protofilament microtubules in Caenorhabditis elegans (18,
19). Thus, the consequences, if any, of producingmultiple-tu-
bulin isoforms in vertebrate organisms remain elusive.
Our recent work showed that conditional overexpression of
isotypes 1, 2, and 4b has no effect onmicrotubule assembly
or drug sensitivity in transfected Chinese hamster ovary
(CHO)2 cells (20). Similarly, expression of neuronal-specific
4a produced very minor effects on microtubule assembly but
was able to increase sensitivity to paclitaxel,most likely through
increased binding of the drug (21). On the other hand, high
expression of neuronal-specific 3 reduced microtubule
assembly, conferred low level resistance to paclitaxel, and
inhibited cell growth (22). The most dramatic effects, however,
were seen in cells transfected with 5, a minor but widely
expressed isotype (23). Evenmodest overexpression of this iso-
type reduced microtubule assembly and conferred paclitaxel
resistance, whereas high levels of expression (50% of total
tubulin) caused fragmentation and a near complete loss of the
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with 5 overexpression, this isotype was recently shown to be
required for normal mitotic progression and cell proliferation
(25).
Because of its importance for cell division, and the extreme
phenotype associated with its overexpression, we sought to
identify the structural differences between 5-tubulin and its
more “normal” homolog, 1. Although there are 40 amino acid
differences between the 2 isotypes, we report that most of the
unique properties of 5 can be attributed to the presence of
serine in place of cysteine at residue 239. This residue faces the
colchicine binding pocket and is very close to a highly con-
served Cys-354 residue. We propose that Ser-239 found in
5-tubulinmay prevent formation of a disulfide bond that nor-
mally stabilizes microtubules.
EXPERIMENTAL PROCEDURES
Construction of HA-tagged 1/5 Chimeric Tubulin Genes—
The starting materials for the generation of chimeric tubulins
were a CHO 1-tubulin cDNA (GenBankTM accession number
U08342) and a mouse 5-tubulin cDNA (GenBankTM acces-
sion number BC008225). Both cDNAsweremodified to encode
a C-terminal hemagglutinin (HA) tag to facilitate separation
and detection of the transfected tubulin and were cloned into a
pTOPneo vector to permit tetracycline-regulated expression
(26). Prior to the generation of chimeras, the pTOPHA1 was
modified by site-directed mutagenesis to remove a BamHI site
at the 5-end of CHO HA1 cDNA, and the resulting plasmid
was named pTOPHA1-BamHI. Subsequent steps utilized two
conserved internal restriction sites, BspHI (at codon 163) and
BamHI (at codon 344), to generate six distinct chimeras
named according to the isotype sequences present in the
N-terminal (amino acids 1–163), central (amino acids 164–
344), and C-terminal (amino acids 345–444/447) regions of
the protein. For example, HA151 contains 1 sequences at
the N-terminal and C-terminal regions with a 5 sequence
in the middle. Restriction enzymes were from Promega
(Madison, WI). Site-directed mutagenesis of various con-
structs was carried out using the QuikChange mutagenesis
kit (Stratagene, La Jolla, CA).
Transfection and Isolation of Stable Transfected Cell Lines—
CHO tTA cells harboring the tetracycline-regulated transacti-
vator (26) were transfected with different chimeric -tubulin-
containing plasmids using Lipofectamine (Invitrogen) as
described by themanufacturer. Following transfection, the cells
were maintained in MEM (Mediatech Inc., Manassas, VA)
supplemented with 5% fetal bovine serum (Gemini Bio-Prod-
ucts,W. Sacramento, CA). To determine the efficiency of trans-
fection, a sterile coverslipwas placed in the dish prior to seeding
the cells, and the percentage of cells expressing the transfected
tubulin was determined by immunofluorescence using a rabbit
antibody against the HA tag (Bethyl Laboratories, Montgom-
ery, TX) followed by an Alexa-488-conjugated goat anti-rabbit
IgG (Invitrogen). To obtain stably transfected cells, the trans-
fected population was replated in 60-mm dishes containing
MEM, tetracycline (1 g/ml), and G418 (2 mg/ml). After 7–8
days resistant colonies were isolated and screened for expres-
sion of the HA-tubulin or pooled and maintained as a total
G418-resistant population.
Immunofluorescence—Cells were grown on sterile glass cov-
erslips in MEM for 48–72 h, washed in PBS, and extracted in
MTB buffer (20 mM Tris-HCl, pH 6.8, 1 mM MgCl2, 2 mM
EGTA, 0.5% Nonidet P-40) containing 4 g/ml paclitaxel for 2
min at 4 °C. Fixation was carried out in methanol at20 °C for
15 min followed by rehydration in PBS for 10–15 min. The
fixed cells were incubated in PBS containing 1:100 dilutions of
mouse -tubulin antibody DM1A (Sigma-Aldrich) and rabbit
HA antibody (Bethyl) for 1 h at 37 °C in a humid chamber. The
coverslips were then washed in PBS and incubated for an addi-
tional hour in 1:100 dilutions of Alexa 488-conjugated goat
anti-rabbit IgG and Alexa 594-conjugated goat anti-mouse IgG
(Invitrogen) as well as DAPI (1 g/ml). After washing in PBS
the coverslips were inverted onto 5 l of mounting medium
(Biomeda Corp., Foster City, CA), and were viewed by epifluo-
rescence using an Optiphot microscope (Nikon, Inc., Melville,
NY) equipped with a Plan Apochromat 60 1.4 numerical
aperture oil objective and filters tominimize cross-talk between
channels.
Colony Formation Assay—Approximately 100–200 cells
were seeded into the first well of a 12-well dish containing
MEM plus 1 g/ml tetracycline to inhibit the expression of
the transgene. This well was used as a control to estimate the
number of viable cells plated. Two additional wells received 10
times as many cells in MEM containing 200 nM paclitaxel
with or without 1 g/ml tetracycline. The cells were incu-
bated until colonies were visible (7–9 days), the medium was
removed, and the cells were stained with a solution of 0.05%
methylene blue in water as described previously (27). The
plates were rinsed gently with water to remove excess stain,
dried, and photographed.
Electrophoresis and Western Blots—CHO tTA cells or the
same cells transfectedwithHA-tubulin cDNAswere grown in
24-well dishes and lysed in 1% SDS. Proteins were precipitated
by adding 5 volumes of acetone, resuspended in 1 sample
buffer (0.0625 M Tris-HCl, pH 6.8, 2.5% SDS, 5% 2-mercapto-
ethanol, 10% glycerol), fractionated on a 7.5% polyacrylamide
SDS minigel, and transferred to PROTRAN nitrocellulose
membranes (Schleicher and Schuell, Keene, NH). The mem-
branes were blocked by incubating in PBST (PBS with 0.05%
Tween 20) containing 3%drymilk. Afterwashing in PBST three
times themembraneswere incubated 1 h in a 1:5,000 dilution of
mouse monoclonal antibody 18D6 specific for the N-terminal
amino acids of all -tubulin isoforms (28). A 1:25,000 dilution
of actin-specific mouse monoclonal antibody C4 (Chemicon
International Inc., Temecula, CA) was also added to act as an
internal control. After washing 3 times in PBST, the blots were
incubated 1 h in a 1:2,000 dilution of Alexa 647-conjugated goat
anti-mouse IgG (Invitrogen). Immunoreactive bands were
detected by capturing fluorescence emission on a STORM 860
imager (Molecular Dynamics Inc., Sunnyvale, CA). In some
experiments, - or -tubulin was detected using mouse anti-
bodies DM1A and Tub 2.1 (Sigma).
Measurement of Polymerized and Unpolymerized Tubulin—
Cells were grown in 24-well dishes for 2 days and lysed in 100l
ofMTBbuffer containing 0.14MNaCl and 4g/ml paclitaxel to
keep the polymerized microtubules intact (29). The solubilized
cells were scraped from the wells and transferred to 1.5-ml
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microcentrifuge tubes. Residual material was washed from the
wells with 100 l of the lysis buffer and mixed with the initial
lysate. To solubilize any remaining residue, 100 l of 1% SDS
was added to the wells. The lysates were briefly mixed and cen-
trifuged at 12,000  g for 15 min at 4 °C. The supernatants
carrying the unpolymerized tubulin were transferred to fresh
tubes. The pellets containing the polymerized tubulin were
resuspended in 50 l water and combined with the residues
solubilized in SDS from the corresponding wells. To each sam-
ple (supernatant and pellet) 4 l of a bacterial lysate containing
GST--tubulinwas added as a control for any losses incurred in
subsequent steps. Proteinswere precipitated using 5 volumes of
acetone and resuspended in 30 l of 1 sample buffer. Equal
volumes of samples were fractionated on a 7.5% polyacrylamide
SDSminigel and transferred to a nitrocellulosemembrane. The
membrane-bound proteins were incubated with mouse anti-
bodies DM1A (-tubulin) and C4 (actin), followed by Alexa
647-conjugated goat anti-mouse IgG as described above. Bands
corresponding to -tubulin, GST--tubulin, and actin were
quantified by using ImageJ software (National Institutes of
Health) using the “gelplot1” macro. The percentage of tubulin
polymerized into microtubules was calculated by normalizing
tubulin in the supernatant and pellet fractions to the amount of
GST--tubulin, dividing the normalized value from the pellet
by the sum of the values from supernatant and pellet, and mul-
tiplying the fraction by 100.
RESULTS
Construction of Chimeric HA-tubulins—We previously
reported that elevated production of 5-tubulin causes micro-
tubule disruption and paclitaxel resistance in transfected cells
(24), whereas transfection of 1, 2, and 4b isotypes does not
(20). In an effort to identify the structural elements that might
account for the unique effects of 5, we aligned its amino acid
sequence with 1, the most abundant and widely distributed
isotype. Excluding the hypervariable region at the C-terminal
end, 29 internal amino acid differ-
ences (conserved plus non-con-
served) were found (Fig. 1).
Because we didn’t know whether
the phenotypes conferred by over-
expression of 5 were the result of
single or multiple amino acid differ-
ences, we began our search for the
relevant changes by carrying out
domain swapping experiments
between 5- and 1-tubulin. Two
conserved endonuclease sites,
BspH1 (codon 163) and BamH1
(codon 344), were found that
allowed us to create 6 in-frame chi-
meric -tubulin cDNAs. Each chi-
mera was named according to the
isotype sequence present in each of
three segments beginning with the
N terminus; e.g. 515 has 5 at the
N and C termini with a 1 sequence
in the center (Fig. 2). All the differ-
ent chimeric cDNAs were sequenced to make sure they were
in-frame andwould produce the desired fusion proteins. To aid
in identifying and measuring their levels of expression, the chi-
meric -tubulin cDNAs were constructed to encode an HA tag
at the C-terminal end of the proteins. Production of tubulin
containing the C-terminal HA tag also served as confirmation
that the cDNAs were in-frame.
The Central and the C-terminal Regions of 5-Tubulin Con-
tain Sequences That Cause Microtubule Disassembly—CHO
cells stably transfected with each chimeric tubulin cDNA were
selected using G418; tetracycline was also included to inhibit
transcription of the transgene and thereby limit any potential
toxicity. The G418-resistant cell populations were then tested
for effects of chimeric -tubulin gene expression on microtu-
bule organization by incubating them in tetracycline-free
media for 3 days to allow transgene expression and viewing the
cells by immunofluorescence microscopy. As discussed in a
previous publication (24), we were able to estimate the expres-
sion of ectopic -tubulin based on dual staining with anti-HA
tag (green fluorescence) and anti--tubulin (red fluorescence)
antibodies. Using a triple bandpass filter, microtubules incor-
porating high levels of chimeric HA-tubulin appeared green,
cells with intermediate levels of expression appeared yellow to
orange, and cells with low expression appeared red. To main-
tain consistency in the analysis, we show only the cells that
appeared green, i.e. had a high level of transgene expression, to
illustrate results throughout the figures. Also note that in Fig. 2
the nuclei were pseudocolored red in place of the blue DAPI
fluorescence to make them stand out more clearly.
We found that all the chimeric tubulins exceptHA511were
able to induce microtubule disruption when expressed at high
levels. The cells expressing HA511 (Fig. 2C) had microtubule
assembly that was indistinguishable from wild-type or HA1
(Fig. 2A)-transfected cells indicating that amino acid differ-
ences in the N-terminal region of 5 are not sufficient to cause
microtubule disruption. In contrast, cells producing chimeric
FIGURE 1. Alignment of 1 and 5 tubulin. The CHO Class I (U08342) and mouse Class V -tubulin
(NP_080749) protein sequences were aligned using MacVector (Accelrys Inc., San Diego, CA). Shared BspH1
and BamH1 sites that were used in subsequent experiments are shown. Amino acids in 5 that differ from 1
are underlined.
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tubulin that contained either the central or C-terminal region
of 5 had disrupted microtubules and were multinucleated
(Fig. 2, D–H), making their appearance similar to cells trans-
fected with intact HA5 (Fig. 2B). Low expression of these
hybrids produced little or no microtubule disassembly or
multinucleation, whereasmoderate expression produced inter-
mediate phenotypes, thus indicating that the effects of expres-
sion were dose-dependent (data not shown). The presence of
theN-terminal region of5with either the central or theC-ter-
minal part, as in constructs HA551 and HA515, did not
reverse the ability of those domains to disrupt microtubules.
We concluded that the central and the C-terminal regions of
5, but not the N-terminal domain, must each contain at least
one or more amino acids responsible for microtubule
disassembly.
The N-terminal Region of 5-Tubulin Is Required for Pacli-
taxel Resistance—Studies of numerous tubulin mutations have
led to the observation that alterations in microtubule assembly
are almost always accompanied by a change in cell sensitivity to
agents that affect microtubule assembly (30, 31). Similarly,
overexpression of 5-tubulin inhibited microtubule assembly
and conferred paclitaxel resistance (24). To determine whether
paclitaxel resistance is encoded within the same regions of 5
that encode microtubule disrupting activity, colony formation
assays were performed by exposing
transfected G418-resistant cell pop-
ulations to a lethal dose of pacli-
taxel. The results summarized in
Fig. 2 indicated that only cells trans-
fected with HA551 (Fig. 2F) and
HA515 (Fig. 2G) formed colonies
in paclitaxel. Under identical condi-
tions, cells expressing HA5 (Fig.
2B) but not HA1 (Fig. 2A)
formed viable colonies in the drug.
In all cases where tetracycline was
added to inhibit expression of the
ectopic tubulin, transfected cells
failed to form colonies in pacli-
taxel indicating that transgene
expression was necessary for drug
resistance (data not shown). Given
our previous experience, we found
it surprising that three of the
hybrid tubulins that disrupted
microtubule assembly (HA151,
HA115, and HA155) failed to
confer resistance to paclitaxel.
Although the N-terminal segment
of 5 was not sufficient to cause
microtubule disruption or confer
paclitaxel resistance on its own
(Fig. 2, C and C), its presence in
combination with either the cen-
tral or the C-terminal domain was
needed for drug resistance. The
results suggest that interactions
between the N-terminal domain
and elements in the central and C-terminal domains cause
differences in the response of microtubules to paclitaxel in
each of the two isotypes.
TheHighly Divergent C-terminal Tail of 5 Is Not Involved in
Microtubule Disruption or Drug Resistance—Apart from the
very divergent last 15 amino acids, 1 and 5 tubulins differ at
only 4 additional amino acids in the C-terminal fragment.
Because there are so many differences clustered in the last 15
amino acids (see Fig. 1), we first sought to determine whether
this region by itself could cause microtubule destabilization.
Hence, two further chimeric tubulins were constructed: one in
which amino acids 345–417 were from 5 and the rest of the
C-terminal fragment was from 1 tubulin (HA1151), the
other inwhich only amino acids 417–447were from5-tubulin
(HA1115) (Fig. 3). Like the parental HA115 hybrid tubulin,
transfection of HA1151 caused microtubule disruption and
multinucleation (Fig. 3B). In contrast, transfection of HA1115
produced no phenotype (Fig. 3A). We therefore conclude that
the divergent amino acids at the extreme C terminus play little
if any role in the ability of 5-tubulin to cause microtubule
disruption.We also did not find any effect of the extremeC-ter-
minal tail on sensitivity to paclitaxel or colcemid (data not
shown).
FIGURE 2. Effects of HA1/5 chimeras onmicrotubule organization and drug sensitivity. CHO tTA cells
were transfected with chimeric HA-tubulins as indicated in the schematics and grown for 3 days in the
absence of tetracycline to induce transgene expression. Cells were then labeled for immunofluorescencewith
DAPI (red) and an antibody to the HA-tag (green) (A–H). The ability of chimeras to confer paclitaxel resistance
was tested by a colony formation assay (A–H). Cells transfected with chimeric tubulins were grown with tet
(left well) or with paclitaxel but no tet (right well) for 7 to 8 days, and surviving colonies were visualized by
staining with methylene blue. Bar 10 m.
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Amino Acid 365 in the C-terminal Domain of 5 Is Impli-
cated in Microtubule Disruption—The HA1151 construct
that retained the ability to disrupt microtubule assembly
encodes only 4 amino acids (Val-351, Ser-365, Ser-386, and
Phe-398) that differ from 1-tubulin. To determine which of
them are involved in destabilizing microtubules, we altered
each of those amino acids in HA115 to the cognate amino
acids in 1 tubulin, and transfected each construct into CHO
cells to assess whether it was still capable of causing microtu-
bule disruption. Of the four amino acid substitutions that were
tested, only S365V caused a complete loss of the microtubule
disrupting activity and left the cells with a normal diploid mor-
phology (Fig. 4A). In contrast, V351T (Fig. 4B), S386T (Fig. 4C),
and F398Y (not shown) substitutions did not prevent HA115
from disrupting microtubule assembly and cell morphology.
We thus conclude that of all the isotype-specific amino acid
differences in the C-terminal segment of HA115 tubulin, only
Ser-365 is necessary for microtubule disruption. To determine
whether alteration of residue 365 is sufficient to disrupt micro-
tubule assembly, we produced a V365S substituted 1-tubulin
in CHO cells and found that it potently disrupted the microtu-
bule cytoskeleton (Fig. 4D).
Amino Acid 239 in the Central Domain Strongly Affects
Microtubule Assembly—Similar experiments were carried out
with HA151 in an attempt to identify the critical amino acid
residues in the central domain of 5 responsible for microtu-
bule disruption. Sequence alignment between 1 and 5 iden-
tified 7 residues (170, 239, 275, 315, 320, 332, and 333) that
differed between the 2 isotypes. Monosubstitution of each
amino acid in HA151 with the corresponding amino acid in
1 failed to completely abolish the ability of the chimeric
tubulin to disrupt microtubules, but an S239C substitution
had the largest effect on reversing the phenotype (supple-
mental Fig. S1).
Given the complexity of trying to eliminate themicrotubule-
disrupting activity of HA151, we instead createdmutations in
HA1-tubulin to look for gain of function. A C239S substitu-
tion caused the most microtubule disruption (Fig. 5A). It also
caused problems in mitosis as evidenced by multiple large and
oddly shaped nuclei in interphase cells. These multinucleated
cells comprised 70% of the transfected cell population com-
pared with only 7% for cells transfected with wild-type HA1.
S275A, A315T, R320P, and V333I substitutions, on the other
hand, had little or no discernible effect on the microtubule net-
work (Fig. 5, B–E) and did not cause any increase in the per-
centage of cells that were multinucleated. Finally, V170M and
N332A substitutions produced minimal disruption of the
microtubules; but at especially high expression, multinucleated
cells become more common and comprised 18–20% of the
transfected cell population (Fig. 5, F, and G). We concluded
from these observations that alteration of residues 275, 315,
320, and 333 had no obvious effect on microtubule assembly
or mitosis, alteration of residues 170 and 332 had weak
effects, and alteration of residue 239 had the greatest effect
on these phenotypes.
To more quantitatively assess the severity of the mutations
that caused weak effects, stable clones of HA1V170M were
isolated. As an example of the results, expression of
HA1V170M in Clone 9 accounted for70% of the total -tu-
bulin (supplemental Fig. S2A), yet the cells retained essentially
normal microtubule assembly (supplemental Fig. S2B). In con-
trast, HA1 clones with amino acid substitutions at residues
239 and 365 had very low levels of microtubule polymer at sim-
ilar levels of expression (described in the next section and Fig.
6). We thus conclude that amino acids residues 170 and 332
play only minor roles in the ability of 5-tubulin to disrupt
microtubule assembly, but we can’t rule out the possibility that
different combinations of these and other amino acids could
produce larger effects. A summary of the mutational data is
provided in Table 1.
BA
FIGURE3.Effectsof theextremeC-terminal tail onmicrotubuleassembly.
Hybrid HA-tubulins (shown as a schematic) were transfected into CHO tTA
cells. After 2 days without tetracycline the cells were stained for immunoflu-
orescencewithDAPI andanantibody to theHA tag.Note that overexpression
of HA1-tubulin containing the extreme C terminus from 5 (1115) had no
effect onmicrotubules or nuclearmorphology (A), but that HA1151-tubulin
disrupted microtubules and produced multinucleation (B). Bar 20 m.
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FIGURE 4. Ser-365 of 5-tubulin is implicated in microtubule disruption.
Immunofluorescence with an antibody to the HA tag was used to test the
ability of mutated HA115 to disrupt microtubules in transfected cells. Only
an S365V (A) mutation completely reversed the ability of HA115 to disrupt
microtubule assembly; V351T (B) and S386T (C) mutations did not. Transfec-
tion of HA1 containing a V365S mutation strongly disrupted microtubules
(D). Bar 10 m.
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HA1 Substitutions at Residues 239 and 365 Confer Pacli-
taxel Resistance—To determine whether the amino acid differ-
ences in 5 that are responsible for disruption of microtubule
assembly are also responsible for conferring resistance to pacli-
taxel, we transfectedCHOcells withHA1-tubulin cDNAcon-
tainingV365S andC239Smutations and tested the ability of the
cells to form colonies in the presence of normally lethal con-
centrations of the drug. Cells expressing wild-type HA1 failed
to survive in 200 nM paclitaxel, but cells producing each of the
two mutant tubulins formed numerous resistant colonies. In
contrast, cells transfected with HA1-containing mutations
that did not affect microtubule assembly (V170M, A275T,
T315A, R320P, and A332N) behaved like wild-type HA1 and
did not form colonies in paclitaxel indicating that these individ-
ual mutations were not sufficient to confer drug resistance
(data summarized in Table 1).
As a further test for the ability of HA1C239S and
HA1V365S to confer drug resistance, we determined the abil-
ity of paclitaxel to select for cells that produce mutant HA-
tubulin. As observed in previous studies (20, 26, 32), G418-
resistant populations ofmutantHA1-tubulin transfected cells
were heterogeneous, with roughly half of the cells producing
varying levels of the HA-tagged protein (left panels, Fig. 6A).
We reasoned that, if themutant tubulin is capable of conferring
resistance to paclitaxel, then reselecting the G418-resistant
cells in a normally lethal dose of paclitaxel should produce a
population with a much larger fraction of positive cells. As pre-
dicted, immunofluorescence analysis of survivors from a 200
nM paclitaxel selection showed that 99% of the cells were posi-
tive for the ectopic protein (right panels, Fig. 6A). Consistent
with these findings, Western blot analysis (Fig. 6B) demon-
strated that the paclitaxel selected cells (lanes 2 and 4) had
significantly higher levels of mutant HA-tubulin than the
G418-resistant cells (lanes 1 and 3). Thus, by several independ-
ent criteria, C239S andV365Smutations inHA1-tubulin con-
fer resistance to paclitaxel.
Our previous studies showed
that tubulin mutations that reduce
microtubule assembly almost
always confer resistance to pacli-
taxel. To test whether the C239S
and V365S mutations act in a simi-
lar manner, transfected paclitaxel-
resistant cells were grown overnight
with or without paclitaxel. They
were then lysed in a microtubule-
stabilizing buffer and centrifuged to
separate microtubule polymer from
soluble tubulin. We found that
resistant cells grown in paclitaxel
had 35–38% of their total tubulin
in polymerized form, an amount
that is similar to that found in
untreated wild-type cells. In the
absence of paclitaxel, however, the
resistant cells had only15–20% of
their tubulin in the polymerized
form (Fig. 6C). Thus, in agreement
with other drug-resistant cell lines (30, 31), C239S and V365S
mutations confer resistance to paclitaxel by destabilizing the
microtubule network and thereby opposing the action of the
drug.
An S239C Mutation of HA5 Destroys Its Ability to Disrupt
Microtubules and Confer Resistance to Paclitaxel—In contrast
to the transfection of HA1-tubulin, which produced cells with
normal microtubules and sensitivity to paclitaxel (Fig. 7, A and
A), transfection of HA5-tubulin produced large, multinucle-
ated cells with a much less dense, disrupted microtubule net-
work and the ability to grow in a normally lethal dose of pacli-
taxel (Fig. 7, B and B). Although the two tubulin isotypes differ
at 40 residues, only changes in amino acids 239 and 365 were
found to cause a 5-like phenotype when introduced into
HA1-tubulin. To determine whether the same two residues
are required for the ability of 5 to cause the changes shown in
Fig. 7, we “reverted” the amino acids at each of those two posi-
tions in 5 to the corresponding amino acids in 1. The
HA5S365V mutant retained the ability to disrupt microtu-
bules and confer paclitaxel resistance in transfected cells (Fig. 7
(D and D) and Table 1), indicating that this amino acid is not
essential for 5 to exert its effects. However, transfection of an
HA5S239C cDNA produced only normal looking CHO cells
with normal paclitaxel sensitivity (Fig. 7 (C and C) and Table
1). An S239C/S365V double mutant also reverted 5 into
behaving essentially like 1 (Table 1 and data not shown).
These results indicate that Ser-239 is uniquely responsible for
the ability of 5-tubulin to disrupt microtubule assembly and
confer resistance to paclitaxel.
DISCUSSION
Class V-tubulin is an intriguing isotype. It is one of the least
studied forms of tubulin despite the fact that is found in almost
all tissues except brain (23). Measurements have indicated
that it is a minor isotype, comprising10% of the -tubulin in
most tissues (23) and 10–20% of the -tubulin in several cul-
FIGURE 5. Ser-239 of 5-tubulin is involved in disrupting microtubule organization. The variable amino
acids in the central part of 5-tubulin were introduced into HA1 and evaluated for their ability to cause
microtubule disruption. Transfected cells were grown for 3 dayswithout tetracycline to inducemutant protein
expression and then stained with DAPI and an antibody against the HA tag. A C239S mutation (A) produced
strongmicrotubule disruption andmultinucleationwhile S275A (B), A315T (C), R320P (D), and V333I (E) had no
effects. V170M (F) and N332A (G) had weak effects that were only seen at very high levels of expression. Bar
20 m.
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tured cell lines (5). In CHO cells, we and others have reported
that its abundance is only 5% (16, 33). Increased expression of
this isotype can be very toxic (24). We have considerable expe-
rience in overexpressing various tubulin isotypes,mutant tubu-
lins, and microtubule-interacting proteins (20–22, 26, 32,
34–37); yet of all the cDNAs we have transfected, 5-tubulin
produces the most dramatic effects. The types of changes we
see are similar to those we have reported for mutant forms of
1-tubulin, but themagnitude of the changes is generallymuch
greater for 5 transfections. These changes include an altered
cell morphology that results from defects in mitotic progres-
sion. As we and others have previously described, treatments
that alter spindle structure or function cause amitotic delay but
do not trigger apoptosis in CHO cells. Instead, the cells escape
the mitotic checkpoint and continue into G1 without cytokine-
sis to form large, flat cells with fragmented nuclei that result
from the inability of themitotic cells to properly segregate their
chromosomes (38–41). These cells frequently go through sev-
eral aberrant cell cycles to become very large and polyploid
before they die. Immunofluorescence experiments indicate
that 5 overexpression strongly inhibits microtubule assembly,
leaving cells with a very sparse and fragmented microtubule
network (e.g. see Fig. 2B). The conclusion that 5 toxicity arises
from its inhibition of microtubule assembly is consistent with
the observation that themicrotubule-stabilizing drug paclitaxel
is able to counteract the effects of 5 overexpression; i.e.
5-overexpressing cells have been shown to be resistant to the
effects of paclitaxel treatment and are frequently dependent on
the drug for proliferation (24). Despite the toxicity associated
with the overexpression of this isotype, we noted that it is pres-
ent in all proliferating cells that have been examined (5, 16, 23,
33), including CHO cells, which have been in culture since
1954, and have dispensed with many nonessential genes (42–
44). Attempts to deplete this isotype in mammalian cells using
short hairpin RNA produced hyperstable microtubules and
inhibited cell proliferation, indicating that a small amount of5
is necessary for microtubules to function properly (25).
In an effort to understand the molecular basis for the effects
of 5 overexpression, we attempted to identify sequence ele-
ments responsible for its ability to disrupt microtubules. Of the
40 amino acids in 5 that differ from 1-tubulin, an isotype
whose overexpression has no effect on cells, only 2 of them,
FIGURE6.HA1C239SandV365Smutations conferpaclitaxel resistance.
CHO tTA cells expressing HA1 with either C239S or V365S mutations were
selected in the presence of G418 and tet. tet was then removed to allow
transgene expression and the cellswere reselected in paclitaxel.A, cells trans-
fected with the indicated mutant HA1-tubulins and selected for G418 or
paclitaxel (Ptx) resistance were stained with DAPI and an antibody to the HA
tag. Note that the G418 survivors were a mixture of cells with or without
HA1-tubulin expression, whereas the paclitaxel survivors were uniformly
positive for mutant HA1-tubulin expression. Bar 20 m. B, cells selected
for resistance toG418 (lanes 1 and 3) or paclitaxel (lanes 2 and 4) were assayed
for production of the indicated mutant HA-tubulins on Western blots
probed with an antibody to actin (loading control) and an antibody that rec-
ognizes both endogenous () and transfected (HA) -tubulin. Note that
paclitaxel-selected cells produce higher levels of mutant HA-tubulin than
G418-selected cells. C, microtubule assembly in paclitaxel-resistant cells
expressing HA1 with C239S or V365S mutations was compared with wild-
type (WT) CHO cells. The cells were grown in the presence (solid bars) or
absence (open bars) of 200 nM paclitaxel for 2 days, and the extent of tubulin
polymerization (as a percentage of the total cellular tubulin) was measured.
TABLE 1
Summary of mutant effects onmicrotubule assembly and drug
resistance in transfected cells



















a Cells were tested for their ability to form colonies in 200 nM paclitaxel.
b, strong effect;/, marginal effect;, no effect.
cND, not determined.
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Ser-239 and Ser-365, produced significant microtubule disrup-
tionwhen introduced into1. It should be noted that neither of
these residues is within the extreme C-terminal region of -tu-
bulin. Although this region is the most variable among the var-
ious -tubulin isotypes in a given organism, the sequence dif-
ferences are highly conserved across vertebrate species. This
observation has led to the idea thatC-terminal sequencesmight
define and be responsible for functional differences between
tubulin isotypes (45). Our results reported here and elsewhere
(20, 21) do not support this hypothesis for inherent microtu-
bule properties such as assembly or drug sensitivity. They do
not, however, rule out a possible role of C-terminal sequences
in other aspects of microtubule behavior. For example, others
have reported a role for this region of tubulin in ciliary beating
(10, 12), sensitivity to katanin- and spastin-mediated microtu-
bule severing (6, 14), kinesin and dynein mediated motility (13,
46), kinesin I-mediated microtubule depolymerization (8), and
binding of MAP2 and Tau (7, 11).
Although Ser-239 and Ser-365 caused microtubule disrup-
tion when introduced into 1, only Ser-239 appears to be nec-
essary for the disruptive effects of 5; i.e. an S239C substitution
in 5 eliminated all of the effects of this isotype onmicrotubule
assembly and response to paclitaxel, whereas an S365V substi-
tution did not. The results therefore indicate that a serine at
residue 239 is disruptive in both 1 and 5, whereas a cysteine
at that position is conducive to microtubule assembly. We
observed, however, that 115 and 515 constructs disrupted
microtubule assembly despite having a cysteine instead of ser-
ine at residue 239. In these constructs, it is likely that Ser-365
was able to disrupt microtubules just as it did in a 1 back-
ground. This implies that even though some of the changes in
5 relative to 1 appear to be unimportant when viewed in
isolation, they must somehow augment or mitigate the effects
of other amino acid changes, perhaps by altering the overall
conformation of a particular region. We conclude that amino
acid substitutions may be context-sensitive; i.e. a mutation in
one isotype may not necessarily produce the same phenotype
when introduced into a different isotype. This will have impor-
tant consequences for interpreting how tubulinmutations pro-
duce resistance to cancer drugs that target microtubules.
Several laboratories have reported that overexpression of
-tubulin isotypes can affect drug resistance (47). Our
approach using conditional expression of specific cDNAs has
clearly demonstrated that only a subset of -tubulin isotypes
affect the response of cells to drug treatment. Increased expres-
sion of the isotypes that have no effect onmicrotubule assembly
(1, 2, and 4b) also has no effect on the sensitivity of cells to
antimitotic drugs (20). In contrast, increased expression of iso-
types that destabilize microtubule assembly (3 and 5) con-
fers resistance to microtubule-stabilizing drugs such as pacli-
taxel (22, 24). This situation is very similar to extensive
experience in several laboratories, including our own, that
study mutations in 1-tubulin (30, 31, 48). In the case of these
mutants, alterations that reduced the extent of microtubule
assembly increased resistance to drugs that stabilize microtu-
bules and increased sensitivity to drugs that destabilize micro-
tubules. The converse was also true; i.e. alterations in 1-tubu-
lin that increased the extent of microtubule assembly increased
resistance to drugs that destabilize microtubules but increased
sensitivity to drugs that stabilizemicrotubules (29, 49). It would
appear that the effects of -tubulin isotype expression mimic
effects we and others have noted in cells that express mutant
forms of 1-tubulin. Thus, we also looked at the ability of
mutant 5-tubulin to confer resistance to paclitaxel. As
expected, drug resistance again tracked closely with effects of
missense mutations on microtubule disruption in both 1 and
5, but some of the chimeras behaved abnormally. Although
151, 115, 551, 515, and 155 all caused microtubule dis-
ruption, only 551 and 515 conferred resistance to paclitaxel.
The reason why 151, 115, and 155 failed to confer resist-
ance is unclear, but it suggests that the N-terminal region of 5
is necessary for paclitaxel resistance even though it produces no
phenotype when it is fused onto 1-tubulin to produce 511
(Fig. 2). We conclude that there must be interactions of the
N-terminal domainwith the central andC-terminal domains of
5 that influence the ability of paclitaxel to compensate for
FIGURE 7. Amino acid Ser-239 in 5-tubulin is essential for microtubule
disruption and paclitaxel resistance. HA5-tubulin was mutated at posi-
tions 239 and 365 and tested for its ability to disruptmicrotubules and confer
resistance to paclitaxel. G418-resistant populations of cells that had been
transfected with HA1 (A), HA5 (B), HA5S239C (C), or HA5S365V (D) were
grown for 3 days without tet, then stained with DAPI and an antibody to the
HA tag. Note that the S239C (C), but not the S365V (D) substitution reversed
the effects of HA5 on microtubules and nuclear morphology. The same
G418-resistant populationswere tested for their ability to survive exposure to
200 nM paclitaxel (A–D). Cells were grown with tet (left well) or with pacli-
taxel but no tet (rightwell). Note that the S239C substitution also reversed the
ability of HA5 to confer drug resistance. Bar 20 m.
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mutational effects on microtubule structure and assembly.
These interactions may also explain why alteration of residue
365 caused severe microtubule disruption in the case of 1 and
some 1/5 chimeras, but had little effect in a purely 5
background.
The discovery that alteration of Ser-239 in 5-tubulin was
sufficient to reverse the effects of 5 overexpression on micro-
tubule disruption, mitotic progression, and paclitaxel resist-
ance was unexpected and points to a central role of that residue
in microtubule assembly. An alignment of vertebrate -tubu-
lins indicates that residue 239 is a cysteine in 1, 2, 4a, and
4b; i.e. isotypes whose overexpression has little or no effect on
normal microtubule assembly. On the other hand, the same
residue is a serine in 3 and 5; i.e. isotypes whose overexpres-
sion disrupts microtubule assembly (22, 24). Molecular model-
ing studies (Fig. 8) indicate that residue 239 is close to a highly
conserved Cys-354 residue. Moreover, the two cysteines move
closer to one another when tubulin goes from its unassembled
to assembled conformation. Using the “curved” (colchicine-
containing, unassembled) conformation of tubulin (structure
1SA0) (50), the distance between Cys-239 and Cys-354 is8.3
Å (Fig. 8A). In the “straight” (paclitaxel-containing, assembled)
conformation (structure 1JFF) (51), however, this distance
decreases to 4.1 Å (Fig. 8B). We propose that microtubules
composed of isotypes containing a Cys-239 residue may be sta-
bilized by the ability of -tubulin to form a disulfide with Cys-
354 that would favor the straight assembly-competent confor-
mation. Increasing the incorporation of tubulinwith an Ser-239
residuewould then increasingly destabilize themicrotubule lat-
tice by diluting out the number of subunits that are capable of
forming the disulfide bond. Although the 4.1-Å distance
between Cys-239 and Cys-354 would appear to be too large for
the formation of a disulfide, it should be noted that the crystal
structure on which these measurements were based was
obtained from electron diffraction patterns of zinc sheets pre-
pared from brain tubulin that is rich in the 3 isotype (51).
Thus, it is possible that the distance between Cys-239 and Cys-
354 in true microtubules formed from other isotypes might
actually be much closer.
Although this mechanism for the role of Cys-239 in micro-
tubule assembly is speculative, it fits well with previous studies
that have indicated a role for disulfide formation in regulating
microtubule assembly. For example, studies in yeast indicate
that mutations C354S and C354A result in fewer microtubules
(52). Chemical approaches using mammalian tubulin have
demonstrated that Cys-239 and Cys-354 are the most reactive
cysteines in -tubulin and that their modification reduces
microtubule assembly (53). Similarly, inhibiting disulfide for-
mationwith dithiothreitol has been reported to reduce the abil-
ity of tubulin to assemble in vitro (54). Finally, it has been
reported that thioredoxin and thioredoxin reductase are asso-
ciated with microtubules in vivo (55), and this has led to spec-
ulation that thiol-disulfide exchange could play an important
role in regulating microtubule assembly (53, 54).
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